Oricula Therapeutics LLC logo

Oricula Therapeutics LLC

Oricula Therapeutics, LLC, is working to develop the first medication approved to prevent hearing loss. Our first product will prevent the hearing loss that is a frequent side effect of the administration of an important class of antibiotics, the aminoglycosides. Reducing or eliminating hearing loss as a side effect of aminoglycoside therapy would allow broader worldwide use of these important antibiotics for the treatment of life-threatening bacterial infections, such as pneumonia, endocarditis, neonatal septicemia and multi-drug resistant tuberculosis. The FDA has allowed our Investigational New Drug (IND) filing for this product to move forward to early human testing.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.oricularx.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
474 39th Avenue East, WA 98112
Seattle
United States
Email
Contact Number
+1 206-322-7526

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/oricula-therapeutics-llc” connections=”true” suffix=””]